
    
      This study will be conducted on 7 cohorts of cancer patients and 1 cohort of non-cancer
      subjects (age and gender matched) with a sample size of 30 patients in each cohort:

      All enrolled patients will be asked to provide blood samples (2 x 10cc Heparin Tubes) at the
      following time points:

        -  Baseline: before the administration of the first dose of the SARS-CoV-2 vaccine (within
           4 weeks).

        -  Before the second dose of the SARS-CoV-2 vaccine (within 7 days).

        -  Follow-up: after 3, 6, 9 and 12 months after the second dose of the SARS-CoV-2 vaccine.
           A +/- 14 days window is allowed at each follow-up time point.
    
  